Novartis Ag (NVS) Liabilities and Shareholders Equity (2009 - 2025)

Novartis Ag (NVS) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $110.9 billion in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 8.51% year-over-year to $110.9 billion in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $215.3 billion (up 7.81% YoY) and the FY2025 annual result came in at $110.9 billion, up 8.51% from the prior year.
• Liabilities and Shareholders Equity grew to $110.9 billion in Q4 2025 per NVS's latest filing, from $104.4 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $131.8 billion in Q4 2021, with the low at $97.5 billion in Q2 2024.
• Average Liabilities and Shareholders Equity over 5 years is $112.2 billion, with a median of $111.0 billion recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity dropped 14.91% in 2023 and increased 8.51% in 2025.
• Novartis Ag's Liabilities and Shareholders Equity stood at $131.8 billion in 2021, then decreased by 10.88% to $117.5 billion in 2022, then decreased by 14.91% to $99.9 billion in 2023, then increased by 2.3% to $102.2 billion in 2024, then climbed by 8.51% to $110.9 billion in 2025.
• Business Quant data shows NVS's Liabilities and Shareholders Equity at $110.9 billion in Q4 2025, $104.4 billion in Q2 2025, and $102.2 billion in Q4 2024.